Showing results (871-880 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 10, 2025
Targeting neuroblastoma with hydroxamic acid based HDAC1 and HDAC2 inhibitors: Insights from in vitro and in vivo studiesPadmini Pai, Yashaswini Reddy, Ipshita Das, et al.
Investigational New Drugs|July 8, 2025
Clinical presentation of PD-1/PD-L1 immune checkpoint inhibitors induced cystitisJian Xiao, Shanting Tang, Zhi Xia, et al.
Investigational New Drugs|June 25, 2025
Understanding the differentiation syndrome in acute promyelocytic leukemia: a comprehensive updated reviewNahed Damaj, Nadim Elias, Toufic Zeidan, et al.
Investigational New Drugs|September 17, 2025
Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumorsAlejandro Falcón, Santiago Ponce, Gregory M Cote, et al.
Investigational New Drugs|June 9, 2025
Clinical characterizations, management, and prognosis in immune checkpoint inhibitor-induced myelitisYi-Xiao Li, Rui-Yun Wang, Zhi-Hang Lu, et al.
Investigational New Drugs|June 6, 2025
A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast CancerAva Safaroghli-Azar, Laychiluh B Mekonnen, Ramin Hassankhani, et al.
Investigational New Drugs|February 19, 2024
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinomaKathryn E Beckermann, Amita Patnaik, Ira Winer, et al.
Investigational New Drugs|February 12, 2024
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II studyMiaomiao Gou, Yong Zhang, Zhikuan Wang, et al.
Investigational New Drugs|March 14, 2024
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumorsMaxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, et al.
Investigational New Drugs|February 1, 2024
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancerNaoyuki Nogami, Takaaki Tokito, Yoshitaka Zenke, et al.
Pageof 372